Coherus Oncology ends $92.5M stock sale program
Coherus Oncology, Inc. (CHRS) is formally ending its existing at-the-market equity offering program under a prior sales agreement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
424B3
Rhea-AI Filing Summary
Coherus Oncology, Inc. (CHRS) is formally ending its existing at-the-market equity offering program under a prior sales agreement. Under that agreement, the company could offer and sell common stock with an aggregate offering price of up to $92,500,000, and had previously registered the offer and sale of up to $64,880,054 of common stock under a January 2026 prospectus. On August 17, 2026, Coherus notified the agent that it was terminating the sales agreement because it is entering into a new sales agreement with a different agent. This supplement terminates the continuous offering under the January 2026 prospectus and the related sales agreement.
Key Figures
Maximum aggregate offering price under Sales Agreement: $92,500,000
Common stock registered under January 2026 Prospectus: $64,880,054
Sales Agreement termination notice date: August 17, 2026
3 metrics
Maximum aggregate offering price under Sales Agreement
$92,500,000
Common stock that could be offered and sold in at-the-market offerings
Common stock registered under January 2026 Prospectus
$64,880,054
Offer and sale of common stock registered for the ATM program
Sales Agreement termination notice date
August 17, 2026
Date Coherus notified the agent it was terminating the Sales Agreement
Key Terms
at the market offerings, Sales Agreement, prospectus supplement, continuous offering
4 terms
at the market offerings financial
"in sales deemed to be “at the market offerings” as defined in Rule 415"
At-the-market offerings are a way for a company to raise cash by selling newly issued shares directly into the open market at the current trading price through a broker, rather than in a single large sale. Think of it like topping up a gas tank a little at a time at whatever the pump price is; it gives the company flexibility to raise money when conditions are favorable but can increase the number of shares outstanding and dilute existing investors, and frequent or large sales can put downward pressure on the stock price.
Sales Agreement financial
"we entered into a sales agreement (the “Sales Agreement”) with Cowen and Company"
A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.
prospectus supplement regulatory
"This Supplement No. 1 to Prospectus Supplement (this “Supplement No. 1”)"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
continuous offering financial
"The purpose of this Supplement No. 1 is to terminate our continuous offering"
Offering Details
ATM · Up to $64,880,054
Offering
Offering Type
ATM
Securities Offered
Common stock
Offering Amount
Up to $64,880,054
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Coherus Oncology, Inc. (CHRS) change in this 424B3 supplement?
Coherus Oncology, Inc. filed a supplement to terminate its continuous at-the-market offering of common stock under the January 2026 prospectus and the existing sales agreement with the agent.
How large was Coherus Oncology’s (CHRS) prior ATM program?
Under its prior sales agreement, Coherus Oncology could offer and sell common stock with an aggregate offering price of up to $92,500,000, and it had registered the offer and sale of up to $64,880,054 of common stock under the January 2026 prospectus.
When did CHRS terminate its existing sales agreement for the ATM program?
On August 17, 2026, Coherus Oncology notified the agent that it was terminating the sales agreement in accordance with its terms.
Why is Coherus Oncology (CHRS) terminating its ATM sales agreement?
Coherus Oncology is terminating the sales agreement because it is entering into a new sales agreement with a different agent, and this supplement serves to end the continuous offering under the prior arrangement.
Does Coherus Oncology (CHRS) register new securities in this 424B3?
No. The supplement does not register new securities; it amends prior disclosure to terminate the continuous offering of previously registered common stock under the January 2026 prospectus and the related sales agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-291520
SUPPLEMENT NO. 1 TO PROSPECTUS SUPPLEMENT DATED JANUARY 23, 2026
(To prospectus supplement dated January 23, 2026 and prospectus dated December 8, 2025)
(To prospectus supplement dated January 23, 2026 and prospectus dated December 8, 2025)
![[MISSING IMAGE: lg_coherusoncology-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0001512762/000110465926103239/lg_coherusoncology-4c.jpg)
Coherus Oncology, Inc.
This Supplement No. 1 to Prospectus Supplement (this “Supplement No. 1”) amends and supplements the information in the prospectus supplement dated January 23, 2026 (the “January 2026 Prospectus Supplement”) and base prospectus dated December 8, 2025 (together with the January 2026 Prospectus Supplement, the “January 2026 Prospectus”) of Coherus Oncology, Inc. (“we,” “us” and “our”). This Supplement No. 1 should be read in conjunction with and is qualified in its entirety by reference to the January 2026 Prospectus, except to the extent that the information herein amends or supersedes the information contained therein.
On November 8, 2022 we entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (the “Agent”), as amended on May 15, 2023 and September 11, 2023, which was assigned to TD Securities (USA) LLC. In accordance with the terms of the Sales Agreement, we could offer and sell shares of our common stock having an aggregate offering price of up to $92,500,000 at any time and from time to time through or to the Agent, acting as sales agent or principal, in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “ATM Program”). We previously filed the January 2026 Prospectus to register the offer and sale of up to $64,880,054 of shares of our common stock, from time to time under the terms of the Sales Agreement. On August 17, 2026, we notified the Agent we were terminating the Sales Agreement in accordance with its terms because we are entering into a new sales agreement with a different agent.
The purpose of this Supplement No. 1 is to terminate our continuous offering under the January 2026 Prospectus and the Sales Agreement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this Supplement No. 1 or the January 2026 Prospectus. Any representation to the contrary is a criminal offense.
August 28, 2026